European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 5, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:40

Human medicines European public assessment report (EPAR): Vevzuo, denosumab, Date of authorisation: 25/06/2025, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:30

Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:25

Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Date of authorisation: 06/02/2009, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Date of authorisation: 06/02/2009, Revision: 29, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:20

Human medicines European public assessment report (EPAR): Zarzio, filgrastim, Date of authorisation: 06/02/2009, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 17, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:14

Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Vydura, rimegepant, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 15:02

Human medicines European public assessment report (EPAR): Vydura, rimegepant, Date of authorisation: 25/04/2022, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Date of authorisation: 20/07/2009, Revision: 42, Status: Authorised

Submitted by Anonymous (not verified) on 22 October 2026 - 14:50

Human medicines European public assessment report (EPAR): Instanyl, fentanyl, Date of authorisation: 20/07/2009, Revision: 42, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More